Figure 3.

CD27+ B cells with a memory phenotype are less susceptible to cyclophosphamide treatment in patients with systemic lupus erythematosus (SLE) (n = 20). Severely active SLE patients undergoing monthly intravenous cyclophosphamide bolus therapy were followed for a period of 3 to 6 months. Whereas CD27- B cells and CD27++ plasmablasts/plasma cells showed a decrease, the absolute numbers of CD27+ memory B cells did not change significantly. n.s., not significant.

Dörner et al. Arthritis Research & Therapy 2009 11:247   doi:10.1186/ar2780
Download authors' original image